Følg
Jaime Espín Balbino
Jaime Espín Balbino
Escuela Andaluza de Salud Pública
Verifisert e-postadresse på easp.es
Tittel
Sitert av
Sitert av
År
Analysis of differences and commonalities in pricing and reimbursement systems in Europe
J Espin, J Rovira
Brussels: DG Enterprise and Industry of the European Commission 100, 2007
1352007
Risk of second cancers cancer after a first primary breast cancer: a systematic review and meta-analysis
E Molina-Montes, M Requena, E Sánchez-Cantalejo, MF Fernández, ...
Gynecologic oncology 136 (1), 158-171, 2015
1042015
Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: a systematic review and meta-analysis
E Molina-Montes, B Pérez-Nevot, M Pollán, E Sánchez-Cantalejo, J Espín, ...
The Breast 23 (6), 721-742, 2014
1042014
A general framework for classifying costing methods for economic evaluation of health care
Z Špacírová, D Epstein, L García-Mochón, J Rovira, A Olry de Labry Lima, ...
The European Journal of Health Economics 21 (4), 529-542, 2020
732020
Experiences and impact of European risk-sharing schemes focusing on oncology medicines
J Espín, J Rovira, L García
Brussels: Commissioned by the European Commission, Directorate-General …, 2011
652011
How can voluntary cross-border collaboration in public procurement improve access to health technologies in Europe
J Espín, J Rovira, A Calleja, N Azzopardi-Muscat, E Richardson, W Palm, ...
Health systems and policy analysis, policy brief 21, 2016
542016
The impact of biosimilars’ entry in the EU market
J Rovira, J Espín, L García, A Olry de Labry
Andalusian Sch Pub Health 30, 1-83, 2011
532011
Pandemic influenza control in Europe and the constraints resulting from incoherent public health laws
R Martin, A Conseil, A Longstaff, J Kodo, J Siegert, AM Duguet, ...
BMC Public Health 10, 1-10, 2010
522010
Esquemas innovadores de mejora del acceso al mercado de nuevas tecnologías: los acuerdos de riesgo compartido
J Espín, J Oliva, JM Rodríguez-Barrios
Gaceta Sanitaria 24, 491-497, 2010
52*2010
Pharmaceutical pricing and reimbursement information (PPRI)–New PPRI analysis including Spain
S Vogler, J Espin, C Habl
Pharmaceuticals Policy and Law 11 (3), 213-234, 2009
522009
Short-and long-term effects of value-based pricing vs. external price referencing
P Kanavos, E Nicod, J Espin, S Van Den Aardweg
Eminet, LSE, 2010
422010
Personalised medicine as a challenge for public pricing and reimbursement authorities–A survey among 27 European countries on the example of trastuzumab
C Leopold, S Vogler, C Habl, AK Mantel-Teeuwisse, J Espin
Health Policy 113 (3), 313-322, 2013
392013
Working paper 1: External price referencing–review series on pharmaceutical pricing policies and interventions
J Espin, J Rovira, AO de Labry
Geneva: World Health Organization and Health Action International, 2011
392011
Projecting pharmaceutical expenditure in EU5 to 2021: adjusting for the impact of discounts and rebates
J Espin, M Schlander, B Godman, P Anderson, J Mestre-Ferrandiz, ...
Applied health economics and health policy 16 (6), 803-817, 2018
372018
Multiple criteria decision analysis for HTA across four EU member states: piloting the advance value framework
A Angelis, M Linch, G Montibeller, T Molina-Lopez, A Zawada, K Orzel, ...
Social Science & Medicine 246, 112595, 2020
352020
Medicine Prices in Latin American Countries
JE Balbino, JR Forns, CV González
Medicine Price Surveys, Analyses and Comparisons, 61-83, 2019
33*2019
Implementing outcomes-based managed entry agreements for rare disease treatments: nusinersen and tisagenlecleucel
KM Facey, J Espin, E Kent, A Link, E Nicod, A O’Leary, E Xoxi, ...
Pharmacoeconomics 39, 1021-1044, 2021
302021
Evaluation of new medicines in Spain and comparison with other European countries
D Epstein, J Espín
Gaceta sanitaria 34, 133-140, 2020
282020
HTA and decision-making processes in Central, Eastern and South Eastern Europe: Results from a survey
L García-Mochón, JE Balbino, AO de Labry Lima, AC Martinez, EM Ruiz, ...
Health Policy 123 (2), 182-190, 2019
282019
The use of nonrandomized evidence to estimate treatment effects in health technology assessment
S Kent, M Salcher-Konrad, S Boccia, JC Bouvy, C Waure, J Espin, ...
Journal of comparative effectiveness research 10 (14), 1035-1043, 2021
262021
Systemet kan ikke utføre handlingen. Prøv på nytt senere.
Artikler 1–20